Literature DB >> 18028029

Cytochrome P450/redox partner fusion enzymes: biotechnological and toxicological prospects.

Kirsty J McLean1, Hazel M Girvan, Andrew W Munro.   

Abstract

Cytochromes P450 (CYPs) are versatile oxidase catalysts that play pivotal roles in drug metabolism. They are highly regarded as biotechnological tools for their capacity to perform regio- and stereo-selective oxidations. Human CYPs source electrons for oxygen activation from one or more separate redox partner enzymes. However, several CYP enzymes are now known in which the CYP is covalently linked to a reductase system. Some of these systems offer distinct advantages over typical CYPs as efficient, self-contained units capable of important biotransformations, including synthesis of high value chemicals and pharmaceuticals. Protein engineering has been widely applied to produce variant CYP fusions with desirable activities. The review focuses on the nature and diversity of CYP/redox partner fusion enzymes and their biocatalytic potential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18028029     DOI: 10.1517/17425255.3.6.847

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  9 in total

1.  Characterization of a Cleavable Fusion of Human CYP24A1 with Adrenodoxin Reveals the Variable Role of Hydrophobics in Redox Partner Binding.

Authors:  Natalie Jay; Sean R Duffy; D Fernando Estrada
Journal:  Biochemistry       Date:  2022-01-03       Impact factor: 3.162

2.  Metabolic Engineering of Saccharomyces cerevisiae for Heterologous Carnosic Acid Production.

Authors:  Panpan Wei; Chuanbo Zhang; Xueke Bian; Wenyu Lu
Journal:  Front Bioeng Biotechnol       Date:  2022-06-02

Review 3.  Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation.

Authors:  Santosh Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-02       Impact factor: 4.481

4.  Design and improvement of artificial redox modules by molecular fusion of flavodoxin and flavodoxin reductase from Escherichia coli.

Authors:  Patrick J Bakkes; Stefan Biemann; Ansgar Bokel; Marc Eickholt; Marco Girhard; Vlada B Urlacher
Journal:  Sci Rep       Date:  2015-07-16       Impact factor: 4.379

5.  Cytochrome P450-Mediated Phytoremediation using Transgenic Plants: A Need for Engineered Cytochrome P450 Enzymes.

Authors:  Santosh Kumar; Mengyao Jin; James L Weemhoff
Journal:  J Pet Environ Biotechnol       Date:  2012

6.  Concerning P450 Evolution: Structural Analyses Support Bacterial Origin of Sterol 14α-Demethylases.

Authors:  David C Lamb; Tatiana Y Hargrove; Bin Zhao; Zdzislaw Wawrzak; Jared V Goldstone; William David Nes; Steven L Kelly; Michael R Waterman; John J Stegeman; Galina I Lepesheva
Journal:  Mol Biol Evol       Date:  2021-03-09       Impact factor: 16.240

Review 7.  Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolites.

Authors:  Giovanna Di Nardo; Gianfranco Gilardi
Journal:  Int J Mol Sci       Date:  2012-11-28       Impact factor: 5.923

8.  Fusion to Hydrophobin HFBI Improves the Catalytic Performance of a Cytochrome P450 System.

Authors:  Sebastian Schulz; Dominik Schumacher; Daniel Raszkowski; Marco Girhard; Vlada B Urlacher
Journal:  Front Bioeng Biotechnol       Date:  2016-07-04

9.  Engineering of versatile redox partner fusions that support monooxygenase activity of functionally diverse cytochrome P450s.

Authors:  Patrick J Bakkes; Jan L Riehm; Tanja Sagadin; Ansgar Rühlmann; Peter Schubert; Stefan Biemann; Marco Girhard; Michael C Hutter; Rita Bernhardt; Vlada B Urlacher
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.